Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 138

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 138
---
 are an integral part of
these financial statements.

F-33</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 1 – GENERAL

| c. | Liquidity and management plans: |

The Company
is in the research and development (R&D) stage and, as such, has not as of the date of this report generated any revenues from its
current operations. The Company's activities are primarily funded through investment. As of December 31, 2023, the Company raised $5,718
and reported an accumulated deficit of $5,323.

To support
its operations and advance its development program, the Company intends to continue seeking investments. Management anticipates that additional
capital will be necessary to fund its ongoing R&D activities. However, there are currently no binding commitments for further investment,
and there can be no assurance that the Company will secure the required capital on commercially reasonable terms, or at all.

If sufficient
investment cannot be obtained, the Company may need to implement cost-cutting measures, scale back its R&D activities, or delay certain
development programs. Despite these potential challenges, management and the board of directors believe that the Company’s existing
financial resources will be sufficient to sustain its planned operations for at least the next twelve months.

<div align='center'>F-34</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES

The consolidated
Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S.
GAAP”).

| a. | Use of estimates in preparation of Financial Statements: |

The preparation
of consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions
that affect the amounts reported in the consolidated Financial Statements and accompanying notes. The Company evaluates on an ongoing
basis its assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based
upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated Financial Statements, and the reported
amounts of expenses during the reporting periods. Actual results could differ from those estimates.

As applicable
to the